Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
December 6, 2007

Roche to Commercialize ARK's Monitoring Tests for HIV Therapies

  • ARK Diagnostics and Roche Diagnostics signed a letter of intent to negotiate an agreement that would grant Roche distribution and commercialization rights to  ARK's anti-HIV drug monitoring products.

    ARK's tests include immunoassay reagents for certain classes of anti-HIV drugs such as protease inhibitors and nonnucleoside reverse transcriptase inhibitors used to suppress viral replication. The immunoassay reagents are compatible with most automated clinical chemistry analyzers and measure a patient's blood level of anti-HIV drug, according to the companies.

    “We are pleased to partner with Roche   to leverage its distribution and marketing strengths to quickly get the anti-HIV drug monitoring products to market,” states Johnny Valdez, president of ARK. “Roche will be immediately selling and distributing our products worldwide.”

  • You’re all set! Thank you for subscribing to GEN Highlights.